-
公开(公告)号：US09862762B2
公开(公告)日：2018-01-09
申请号：US15104502
申请日：2015-02-05
Applicant: MEDIMMUNE, LLC
Inventor： Partha Chowdhury , Reena Varkey , Meina Liang , Yen-Wah Lee , Katie Streicher , Koustubh Ranade , Ethan Grant , Lydia Greenlees , Yihong Yao , Melissa Parker
CPC classification number: G01N33/6884 , A61K9/0019 , A61K9/0053 , A61K9/0073 , A61K31/137 , A61K31/56 , A61K31/58 , A61K39/3955 , A61K2039/54 , A61P11/00 , A61P11/06 , A61P17/00 , C07K16/18 , C07K16/244 , C07K16/2866 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2319/00 , C07K2319/30 , G01N33/68 , G01N33/6869 , G01N33/6881 , G01N2800/12 , G01N2800/122 , G01N2800/202 , G01N2800/52
Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
-
公开(公告)号：US20200262907A1
公开(公告)日：2020-08-20
申请号：US16063803
申请日：2016-12-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jinging Chen , Robert A. Gasser, JR.
Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
-
公开(公告)号：US20180282417A1
公开(公告)日：2018-10-04
申请号：US15941358
申请日：2018-03-30
Applicant: MedImmune, LLC
Inventor： Brandon Higgs , Koustubh Ranade , Carlos Bais , Philip Brohawn , Michael Kuziora , Rajiv Raja
IPC: C07K16/28 , C12Q1/6886
Abstract: Disclosed are methods for treating cancer (e.g., solid tumor cancers, lung cancer, bladder head and neck cancer) with an anti-PD-L1 antibody in a patient identified as being responsive to anti-PD-L1 antibody therapy by detecting a mutation in one or more disclosed circulating tumor DNA (ctDNA) markers. Also disclosed are methods for determining the efficacy of anti-PD-L1 therapeutic antibody treatment in a patient having lung cancer or bladder cancer comprising detecting variant allele frequency in ctDNA in plasma samples and determining the difference of the variant allele frequency in ctDNA between the first and at least second plasma samples, wherein a decrease in the variant allele frequency in the at least second plasma sample relative to the first plasma sample identifies the anti-PD-L1 antibody treatment as effective. The disclosure also provides methods of identifying a subject having a cancer responsive to a therapy comprising an anti-PD-L1 antibody by detecting the expression of a mutation in one or more circulating tumor DNA (ctDNA) markers.
-
公开(公告)号：US20220373539A1
公开(公告)日：2022-11-24
申请号：US17328816
申请日：2021-05-24
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, JR.
Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
-
公开(公告)号：US20220144935A1
公开(公告)日：2022-05-12
申请号：US17536663
申请日：2021-11-29
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, JR.
IPC: C07K16/24 , G01N33/68 , A61K39/395
Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
-
Patent Agency Ranking
公开(公告)号：US11220541B2
公开(公告)日：2022-01-11
申请号：US16063803
申请日：2016-12-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, Jr.
IPC: C07K16/24 , G01N33/68 , A61K39/395 , A61K39/00
Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
-
公开(公告)号：US10775388B2
公开(公告)日：2020-09-15
申请号：US15106223
申请日：2015-02-05
Applicant: MEDIMMUNE, LLC , ABBOTT LABORATORIES
Inventor： Partha S. Chowdhury , Reena Varkey , Meina Liang , Yen-Wah Lee , Katie Streicher , Koustubh Ranade , Ethan Grant , Lydia Greenlees , Yihong Yao , Melissa Parker , Gerard Davis , Nicolette Jeanblanc , Susan Brophy , Bruce Dille
IPC: G01N33/68 , C07K16/18 , A61P11/06 , A61P17/00 , A61P11/00 , A61K9/00 , A61K31/137 , A61K31/56 , A61K31/58 , A61K39/395 , C07K16/24 , C07K16/28 , A61K39/00
Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
-
公开(公告)号：US20180252728A1
公开(公告)日：2018-09-06
申请号：US15759330
申请日：2016-09-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Grasser, JR.
CPC classification number: G01N33/6869 , A61K2039/505 , C07K16/244 , G01N2800/065 , G01N2800/52 , Y02A50/41
Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
-
9.发明申请公开(公告)号：US20170088628A1
公开(公告)日：2017-03-30
申请号：US15373901
申请日：2016-12-09
Applicant: MedImmune, LLC
Inventor： Yihong Yao , Katie Streicher , Koustubh Ranade , Philip Z. Brohawn , Michael Kuziora
CPC classification number: C07K16/3061 , A61K39/3955 , A61K39/39558 , C07K16/2803 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/178
Abstract: The invention provides compositions and methods featuring the use of miR-629 for identifying subjects responsive to B-cell depleting therapies (e.g., treatment with an anti-CD19 antibody). In other embodiments, the invention features the use of miR-629 to identify subjects as having a B cell malignancy.
-
公开(公告)号：US11016099B2
公开(公告)日：2021-05-25
申请号：US15759330
申请日：2016-09-16
Applicant: AMGEN INC. , MEDIMMUNE, LLC
Inventor： Robert W. Georgantas, III , Chris Morehouse , Brandon Higgs , Koustubh Ranade , Katie Streicher , William Rees , Meina Liang , Raffaella Faggioni , Jing Li , Inna Vainshtein , Yen-Wah Lee , Jingjing Chen , Robert A. Gasser, Jr.
Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.021 seconds)
